PAT and Quality by Design 2014

With QbD becoming a normal integrated part of most companies these days, it is important not to be left behind. Understanding regulatory requirements, PAT data and what will drive companies to have a cost efficient QbD process are all key. Yet still companies are struggling to have a fully implemented QbD system in place.

Join Thought Leaders At The 11th Annual Conference To Enable You To:
- Understand how to prepare a successful QbD submission with regulatory expertise from FDA’s Lawrence Yu and ex-EMEA’s John Purves
- Implement QbD in your company: find out how this has been done by experts in Merck, Teva and Bristol Myers Squibb
- Overcome the problems with implementing QbD in biologics: hear how this has been done in Lonza
- Implement continuous manufacturing with practical advice from the latest pilot plants from Novartis and GlaxoSmithKline
- Understand how the generics industry has complied with the mandatory QbD regulations and the benefits of this within Teva

Speaker and Presenter Information

Dr. Lawrence Yu Acting Deputy Director of FDA's Office of Pharmaceutical Science, Jesus Zurdo, Head of Innovation, Biopharma Development, Lonza, Pedro Hernandez, Director of QbD, Merck Serono, Inna-Ben-Anat, Director, Head of QbD and Product Robustness. Teva Pharmaceuticals, Peter Hamilton, Senior PAT scientist, GLAXOSMITHKLINE